Condition P01
Type 2 diabetes (adults)
Adults (18 years or older) with type 2 diabetes.
380 randomized trials; 247 fitted analyses across 40 outcomes.
Headline results
For each primary outcome, the analysis that pools all doses of each medicine, with the three most favorable estimates against the common comparator. Open an analysis for every treatment, dose and check.
HbA1c change
Mean difference versus Placebo; weeks 20 to 36 (target week 26); 59 trials
- Semaglutide injection-1.57 (-1.84 to -1.31)
- Liraglutide and empagliflozin injection-1.54 (-2.12 to -0.95)
- Exenatide extended release and dapagliflozin injection-1.43 (-1.98 to -0.85)
Lower values favor the treatment.
Body weight change in kilograms (diabetes)
Mean difference versus Placebo; weeks 20 to 36 (target week 26); 50 trials
- Polyethylene glycol loxenatide injection-11.69 (-15.59 to -7.78)
- Tirzepatide injection-9.53 (-12.38 to -6.61)
- Semaglutide injection-4.31 (-5.60 to -3.09)
Lower values favor the treatment.
All cause mortality
Hazard ratio versus Placebo; longest follow-up; 4 trials
- Semaglutide tablet0.52 (0.28 to 0.97)
- Exenatide extended release injection0.86 (0.56 to 1.37)
- Dulaglutide injection0.90 (0.58 to 1.38)
Lower values favor the treatment.
Three point MACE
Hazard ratio versus Placebo; longest follow-up; 6 trials
- Semaglutide injection0.74 (0.42 to 1.35)
- Albiglutide injection0.78 (0.45 to 1.39)
- Semaglutide tablet0.79 (0.43 to 1.46)
Lower values favor the treatment.
All outcomes
Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.
HbA1c changeprimary
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 59 | 33 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 58 | 44 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 21 | 32 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 20 | 19 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 19 | 13 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 19 | 20 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 14 | 26 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 14 | 17 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 13 | 20 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 12 | 13 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 2) | 9 | 13 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled | 9 | 10 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 8 | 9 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 8 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 8 | 12 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 8 | 8 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 8 | 6 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 7 | 9 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 5 | 7 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 5 | 5 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 5 | 12 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 5 | 9 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 4 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 4 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 4 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 4 | 6 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 3 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 3 | 2 | Pairwise meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 3 | 2 | Pairwise meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 8 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 9 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 3 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 2 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 2 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 2 | 6 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 2 | 4 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 3 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 2 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 2) | 2 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 2 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 5 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 3) | 1 | 3 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 3) | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
Body weight change in kilograms (diabetes)primary
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 50 | 28 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 49 | 38 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 19 | 19 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 18 | 18 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 18 | 11 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 17 | 30 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 11 | 12 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 10 | 18 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 10 | 20 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 9 | 13 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled | 8 | 9 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 8 | 6 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 8 | 8 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 8 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 7 | 10 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 7 | 7 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 7 | 8 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 4 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 4 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 4 | 11 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 4 | 8 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 2) | 4 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 3) | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 4 | 3 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 3 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 8 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 3 | 2 | Pairwise meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 3 | 2 | Pairwise meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 9 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 4 | Network meta-analysis |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 2) | 2 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 2 | 3 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 2 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 2 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 2 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 2 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 2 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 3 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately (part 2) | 1 | 5 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 3 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 4) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately | 1 | 4 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 3) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
All cause mortalityprimary
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Hazard ratios | Each dose separately | 4 | 5 | Network meta-analysis |
| longest follow-up | Hazard ratios | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
Three point MACEprimary
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 6 | 7 | Network meta-analysis |
| longest follow-up | Cause specific hazards | Each dose separately | 5 | 6 | Network meta-analysis |
HbA1c below 7 percent
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 17 | 17 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 16 | 23 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 10 | 16 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 10 | 10 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 7 | 8 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 7 | 14 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 3) | 5 | 9 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 4 | 11 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately | 4 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 3) | 4 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 4 | 6 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 4 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 4 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 3 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 3 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 3 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 5) | 2 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 3 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 2 | 4 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 2 | 7 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 2 | 3 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 2) | 2 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 6 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 6) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 7) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 4) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 5) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 6) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 7) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
Level 2 or 3 hypoglycemia (participants)
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 131 | 99 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 128 | 43 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 75 | 37 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 75 | 60 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 74 | 38 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 69 | 70 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 38 | 27 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 32 | 35 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 4 | 5 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 2 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 2 | 5 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 3) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 5) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 6) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 4) | 1 | 2 | Descriptive only |
Systolic blood pressure change
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately | 67 | 44 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled | 67 | 30 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled | 27 | 22 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately | 27 | 33 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 12 | 12 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 12 | 18 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 11 | 10 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 11 | 19 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | Treatment policy | Doses of a drug pooled | 9 | 10 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | While on treatment | Doses of a drug pooled | 6 | 6 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | While on treatment | Each dose separately | 6 | 8 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | While on treatment | Each dose separately | 4 | 8 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 3) | 4 | 5 | Network meta-analysis |
| weeks 36 to 64 (target week 52) | While on treatment | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately | 3 | 5 | Network meta-analysis |
| weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately | 2 | 3 | Network meta-analysis |
| weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 2) | 2 | 3 | Network meta-analysis |
| weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled (part 2) | 2 | 3 | Network meta-analysis |
| weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately (part 2) | 2 | 4 | Network meta-analysis |
| weeks 64 to 130 (target week 104) | While on treatment | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| weeks 64 to 130 (target week 104) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 64 to 130 (target week 104) | While on treatment | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 5) | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Treatment policy | Each dose separately (part 6) | 1 | 2 | Descriptive only |
| weeks 20 to 36 (target week 26) | Treatment policy | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| weeks 20 to 36 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 36 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 36 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 64 to 130 (target week 104) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| weeks 64 to 130 (target week 104) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| weeks 20 to 36 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 36 to 64 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 64 to 130 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 64 to 130 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| weeks 64 to 130 (target week 104) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
Percent body weight change
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 6 | 12 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 6 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 5 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 5 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 4 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 4 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 2 | 5 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 5 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 2 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 2 | 5 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 1 | 3 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 5 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 4) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 104 to 182 (target week 104) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 104 to 182 (target week 104) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| prandial, premixed or basal bolus insulin with or without other drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
Weight loss of 5 percent or more
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 6 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 5 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 5 | 11 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 5 | 13 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 5 | 9 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 4 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 4 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 4 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 3 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | While on treatment | Each dose separately | 3 | 2 | Pairwise meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | While on treatment | Doses of a drug pooled | 3 | 2 | Pairwise meta-analysis |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 5 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 6 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 2 | 5 | Network meta-analysis |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 3) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately (part 3) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately (part 4) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 1 | 4 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 5 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 1 | 3 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 40 (target week 26) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 20 to 40 (target week 26) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
Weight loss of 10 percent or more
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 4 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 4 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 4 | 8 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 4 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 4 | 12 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 2) | 4 | 7 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Doses of a drug pooled | 3 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 2) | 3 | 4 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Treatment policy | Each dose separately | 3 | 7 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 2 | 5 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 2 | 6 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 2 | 4 | Network meta-analysis |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 4 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 1 | 3 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 40 to 104 (target week 68) | Not stated by the trials | Each dose separately | 1 | 5 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Treatment policy | Doses of a drug pooled | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Treatment policy | Each dose separately | 1 | 4 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| no glucose lowering drug (lifestyle only) | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | While on treatment | Each dose separately | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | While on treatment | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 40 to 104 (target week 68) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
Weight loss of 15 percent or more
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| basal insulin with or without non insulin drugs | weeks 40 to 104 (target week 68) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 3 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 6 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Not stated by the trials | Each dose separately | 1 | 3 | Descriptive only |
Weight loss of 20 percent or more
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
Weight loss of 25 percent or more
| Background therapy | Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|---|
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| one or more non insulin glucose lowering drugs | weeks 20 to 40 (target week 26) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
Four point MACE including unstable angina
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
Kidney composite with 40 percent eGFR decline
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
Kidney composite including albuminuria or smaller eGFR declines
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
Hospitalization for heart failure
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 3 | 4 | Network meta-analysis |
| longest follow-up | Cause specific hazards | Each dose separately | 2 | 3 | Network meta-analysis |
Heart failure events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Cause specific hazards | Doses of a drug pooled | 1 | 2 | Descriptive only |
SF-36 physical component summary change
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| weeks 20 to 130 (target week 52) | Not stated by the trials | Doses of a drug pooled | 15 | 10 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Not stated by the trials | Each dose separately | 14 | 16 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately (part 2) | 11 | 14 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled (part 2) | 11 | 9 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Treatment policy | Each dose separately | 2 | 5 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Treatment policy | Doses of a drug pooled | 2 | 3 | Network meta-analysis |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 4 | Descriptive only |
| weeks 20 to 130 (target week 52) | Treatment policy | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | Treatment policy | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | Not stated by the trials | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| weeks 20 to 130 (target week 52) | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
Serious adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 212 | 148 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 211 | 60 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Discontinuation due to adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 110 | 47 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 109 | 99 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 2 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
Nausea
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 196 | 147 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 194 | 59 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
Vomiting
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 170 | 140 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 168 | 53 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Diarrhea
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 183 | 144 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 180 | 57 | Network meta-analysis |
Constipation
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 117 | 109 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 114 | 48 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Discontinuation due to gastrointestinal adverse events
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 43 | 26 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 41 | 46 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
Gallbladder and biliary disease
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately (part 2) | 8 | 20 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 8 | 8 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 3 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 4 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
Acute pancreatitis
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 80 | 103 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 79 | 36 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Medullary thyroid carcinoma
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 34 | 40 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 32 | 22 | Descriptive only |
Thyroid cancer (any)
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 31 | 21 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 31 | 35 | Descriptive only |
Diabetic retinopathy complications
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 10 | 9 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 10 | 21 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
Nonarteritic anterior ischemic optic neuropathy
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
Suicidal ideation or behavior
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
Death by suicide
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 43 | 26 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 43 | 49 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Gastroparesis
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
Intestinal obstruction or ileus
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled | 1 | 2 | Descriptive only |
Pancreatic cancer
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 15 | 20 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 14 | 14 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
Any cancer
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Doses of a drug pooled | 11 | 8 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately | 11 | 12 | Network meta-analysis |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
eGFR total slope
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up from week 52 | Hypothetical (as if everyone stayed on treatment) | Each dose separately | 1 | 2 | Descriptive only |
| longest follow-up from week 52 | Hypothetical (as if everyone stayed on treatment) | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up from week 52 | Not stated by the trials | Each dose separately (part 2) | 1 | 3 | Descriptive only |
| longest follow-up from week 52 | Not stated by the trials | Each dose separately | 1 | 4 | Descriptive only |
| longest follow-up from week 52 | Not stated by the trials | Each dose separately (part 3) | 1 | 2 | Descriptive only |
| longest follow-up from week 52 | Not stated by the trials | Doses of a drug pooled | 1 | 2 | Descriptive only |
| longest follow-up from week 52 | Not stated by the trials | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up from week 52 | Not stated by the trials | Doses of a drug pooled (part 3) | 1 | 2 | Descriptive only |
Acute kidney injury
| Time window | Estimand | Treatments | Trials | Nodes | Analysis |
|---|---|---|---|---|---|
| longest follow-up | Recorded harms | Each dose separately | 16 | 34 | Network meta-analysis |
| longest follow-up | Recorded harms | Doses of a drug pooled | 15 | 14 | Descriptive only |
| longest follow-up | Recorded harms | Doses of a drug pooled (part 2) | 1 | 2 | Descriptive only |
| longest follow-up | Recorded harms | Each dose separately (part 2) | 1 | 2 | Descriptive only |